期刊文献+

DNA修复基因预测非小细胞肺癌放化疗敏感性 被引量:1

原文传递
导出
摘要 化学药物和辐射所诱导的DNA损伤修复通路在肿瘤治疗疗效反应上扮演了重要的角色。肿瘤细胞DNA修复能力增强是肿瘤耐受放化疗的主要机制。DNA修复过程涉及许多基因, 这些基因在遗传学及表遗传学上的改变可影响DNA修复的能力,因此通过检测这些基因的单核苷酸多态性、甲基化状态以及基因的过表达来预测疗效。现综述近年来碱基切除修复基因、核苷酸剪切修复基因及双链断裂修复基因预测非小细胞肺癌放化疗疗效的研究进展。
作者 苏丹 马胜林
出处 《国际肿瘤学杂志》 CAS 2006年第5期361-363,共3页 Journal of International Oncology
  • 相关文献

参考文献1

二级参考文献14

  • 1Risch NJ. Searching for genetic determinants in the new millennium [J]. Nature,2000,405:847- 856.
  • 2Weinshilboum R. Inheritance and drug response [J]. N Engl J Med,2003,348:529- 537.
  • 3Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy [J]. Cancer Treat Rev,1998,24:331- 344.
  • 4Rosell R,Lord RV,Taron M,et al. DNA repair and cisplatin resistance in non-small-cell lung cancer [J]. Lung Cancer,2002,38:217- 227.
  • 5Lunn RM,Langlois RG,Hsieh LL,et al. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency [J]. Cancer Res,1999,59:2557- 2561.
  • 6Schiller JH,Harrington D,Belani CP,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J]. N Engl J Med,2002,346:92- 98.
  • 7Zatloukal P,Petruzelka L,Zemanova M,et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage Ⅲ b and Ⅳ non-small cell lung cancer: a phase Ⅲ randomized trial [J]. Lung Cancer,2003,41:321- 331.
  • 8Xing D,Qi J,Lin D,et al. Polymorphisms of DNA repair genes XRCC1 and XPD and their associations with risk of esophageal squamous cell carcinoma in a Chinese population [J]. Int J Cancer,2002,100:600- 605.
  • 9Xing D,Tan W,Lin D. Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population(review)[J].Oncol Rep,2003,10:1615- 1623.
  • 10Duell EJ,Millikan RC,Pittman GS,et al. Polymorphisms in the DNA repair gene XRCC1 and breast cancer [J]. Cancer Epidemiol Biomarkers Prev,2001,10:217- 222.

共引文献55

同被引文献22

引证文献1

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部